Sveriges mest populära poddar
Pharmaceutical Executive
VetenskapLife Science

The Weight-Loss Gold Rush: Legal and Regulatory Implications

17 min•11 juli 2024
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses:
  • Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs
  • How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs
  • What needs to be done for GLP-1s to be covered
  • Steps companies developing weight-loss medications should take to ensure responsible and ethical practice
  • Advice for investors and financiers who are considering entering the weight-loss medication market

Fler avsnitt av Pharmaceutical Executive

Visa alla avsnitt av Pharmaceutical Executive
Pharmaceutical Executive Daily: FDA Approves Datroway
•2 min
Pharmaceutical Executive Daily: What It Takes to Move Machine Learning
•3 min
Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio
•4 min
Pharmaceutical Executive Daily: TrumpRx Expands to Offer Over 600 Generic Drugs
•3 min
Rethinking Pharma's Go-to-Market Formula
•21 min
Pharmaceutical Executive Daily: FDA Approves Baxdrostat
•2 min
Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra
•3 min
Pharmaceutical Executive Daily: FDA Approves Beqalzi and Inqovi
•4 min
Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu
•3 min
Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen
•3 min

Pharmaceutical Executive med Pharmaceutical Executive Podcast finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.